Vanda Pharmaceuticals Inc (VNDA.OQ)

VNDA.OQ on NASDAQ Stock Exchange Global Market

11.60USD
4:00pm EDT
Change (% chg)

$-0.19 (-1.61%)
Prev Close
$11.79
Open
$11.52
Day's High
$12.07
Day's Low
$11.50
Volume
235,422
Avg. Vol
234,911
52-wk High
$15.51
52-wk Low
$8.34

VNDA.OQ

Chart for VNDA.OQ

About

Vanda Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products for the treatment of central nervous system (CNS) disorders. The Company's product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostat... (more)

Overall

Beta: 1.74
Market Cap(Mil.): $498.55
Shares Outstanding(Mil.): 42.29
Dividend: --
Yield (%): --

Financials

  VNDA.OQ Industry Sector
P/E (TTM): 8.71 69.51 36.12
EPS (TTM): 1.35 -- --
ROI: 46.55 0.51 14.76
ROE: 69.95 0.43 15.63
Search Stocks

Vanda's eczema drug fails mid-stage study, shares fall

- Vanda Pharmaceuticals Inc said its experimental atopic dermatitis drug failed a mid-stage study to treat chronic itching.

04 Mar 2015

UPDATE 1-Vanda's eczema drug fails mid-stage study, shares fall

March 4 - Vanda Pharmaceuticals Inc said its experimental atopic dermatitis drug failed a mid-stage study to treat chronic itching.

04 Mar 2015

Vanda's eczema drug fails mid-stage study

March 4 - Vanda Pharmaceuticals Inc said its experimental atopic dermatitis drug failed a mid-stage study to treat chronic itching, sending its shares down 8.7 percent in after-hours trading.

04 Mar 2015

Competitors

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : Thomson Reuters Stock Report
$25.00
Provider : Stock Traders Daily
$20.00
Provider : New Constructs, LLC
$25.00
Provider : ValuEngine, Inc.
$25.00
Provider : Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks